



WEDNESDAY, 17th OCTOBER 2018 COMMENCING 09:30 AM
AT THE [COPTHORNE HOTEL CARDIFF](#), COPTHORNE WAY,
CULVERHOUSE CROSS, CARDIFF CF5 6DH

AGENDA

- | | |
|---|----------------------------|
| 1. Welcome and introduction | Enclosure |
| 2. Apologies | |
| 3. Declarations of interest | |
| 4. Minutes of previous meeting | 1/AWMSG/1018 |
| 5. Chairman's report (verbal update) | |
| 6. Appraisal 1: Full Submission
Semaglutide (Ozempic[®]) for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise: as monotherapy when metformin is considered inappropriate due to intolerance or contraindications; in addition to other medicinal products for the treatment of diabetes | 2/AWMSG/1018
Appendices |

To protect commercial confidentiality the following appraisals will be held in private

- | | |
|---|----------------------------|
| 7. Appraisal 2: Full Submission (WPAS)
Conestat alfa (Ruconest[®]) for the treatment of acute angioedema attacks in adults and adolescents with hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency | 3/AWMSG/1018
Appendices |
| 8. Appraisal 3: Limited Submission (PAS)
Ipilimumab (Yervoy[®]) as monotherapy for the treatment of advanced (unresectable or metastatic) melanoma in adolescents 12 years of age to <18 years of age | 4/AWMSG/1018
Appendices |

The meeting will now open to the public for the committee decisions

Date of next meeting – Wednesday, 14th November 2018 in Cardiff